The phase II program ARTS (MinerAlocorticoid Receptor antagonist Tolerability Study) was conducted in CKD patients with chronic heart failure and reduced ejection fraction (HFrEF), with spirololactone as a comparator (12). The gene discussed is NR3C2; the disease is congestive heart failure.